

1 Supplemental Table 1. Univariable Comparison of Isolates Bearing Both *qacA/B* and *smr*, One
 2 Gene or Neither *qacA/B* or *smr*.

	<i>qacA/B</i> - positive, <i>smr</i> -positive (n=13)	<i>qacA/B</i> - positive, <i>smr</i> - negative (n=66)	<i>qacA/B</i> - negative, <i>smr</i> - positive, (n=87)	<i>qacA/B</i> - negative, <i>smr</i> - negative, (n=340)	P value
Age, years (IQR)	4.3 (2.3-7.2)	2.76 (0.61-10.3)	1.76 (0.8-5.9)	2.4 (1.2-8.2)	0.3
Female Gender	7 (53.8)	27 (40.9)	41 (47.2)	184 (54.1)	0.2
African American Race	2 (15.4)	20 (30.3)	23 (26.4)	85 (25)	0.7
Hispanic Ethnicity	5 (38.5)	28 (42.4)	38 (43.6)	165 (48.5)	0.6
Underlying Conditions	6 (46.1)	33 (50)	37 (42.5)	101 (29.7)	<0.001
Immunocompromised	2 (15.4)	6 (7.6)	9 (10.3)	19 (5.6)	0.1
Cardiac Disease	2 (15.4)	6 (9.1)	3 (3.4)	7 (2.1)	0.004
Acquisition					0.004

Community-Acquired	9 (69.2)	44 (66.7)	55 (63.2)	209 (79.1)	
Community-Onset	3 (23.1)	14 (21.2)	26 (29.9)	61 (17.9)	
Healthcare					
Associated					
Nosocomial	1 (7.7)	8 (12.1)	6 (6.9)	10 (2.9)	
Methicillin-Resistant	2 (15.4)	13 (19.7)	57 (65.5)	192 (56.5)	<0.001
Clindamycin-Resistant	5 (38.5)	11 (16.7)	16 (18.4)	38 (11.2)	0.017
Vancomycin MIC \geq 2 μg/ml	2 (15.4)	2 (3)	3 (3.4)	5 (1.4)	0.02
Invasive Infection	5 (38.4)	20 (30.3)	24 (27.5)	63 (18.6)	0.03
Hospitalization in Past 3 Months	3 (23.1)	17 (25.8)	20 (22.9)	50 (14.7)	0.058
Antibiotic Use in Past 3 Months	5 (38.5)	30 (45.5)	52 (59.8)	154 (45.3)	0.25
Surgery in Past 3 Months	2 (15.4)	8 (12.1)	14 (16.1)	32 (9.4)	0.26
CVL <i>in situ</i>	2 (15.4)	7 (10.6)	8 (9.1)	17 (5)	0.07

Any CHG Use in Past 3 Months	3 (23.1)	8 (12.1)	12 (13.8)	26 (7.6)	0.05
Infection Leading to Hospital Admission	9 (69.2)	28 (42.4)	50 (57.4)	183 (53.8)	0.17
ICU Admission	2 (15.4)	9 (13.6)	4 (4.6)	13 (3.8)	0.007
Length of Stay, days (IQR)	10 (4-26)	7.5 (3-20)	3 (2-8)	2 (1-6)	<0.001
30 Day Readmission	0	2 (3)	8 (9.1)	8 (2.4)	0.04
All Cause Mortality	0	1 (1.5)	1 (1.1)	1 (0.3)	0.3

3 Continuous variables expressed as medians with interquartile ranges (IQRs). Categorical
4 variables expressed as n (%).

5

6

7

8

9

10

11

12

13

14 **Supplemental Table 2. Invasive vs. Non-Invasive Infections**

	Invasive Infection (n=112)	Non- Invasive Infection (n=394)	Univariable P Value	Adjusted Multivariable P Value	Odds Ratio	95% CI
Age, years	2.6 (0.33- 10.4)	2.4 (1.2- 7.7)	0.13			
Nosocomial Acquisition	23 (20.5)	2 (0.5)	<0.001	0.018	10.8	1.78- 66.2
Underlying conditions	71 (63.4)	106 (26.9)	<0.001	0.014	2.02	1.15- 3.53
Immunocompromised	20 (17.9)	15 (3.8)	<0.001			
Cardiac Disease	10 (8.9)	8 (2)	0.002			
CVL	28 (25)	4 (1)	<0.001	0.11	3.5	0.74- 16.04
Hospitalization in Past 3 Months	52 (46.4)	38 (9.6)	<0.001	0.02	2.6	1.20- 5.63
Antibiotic Use in Past 3 Months	74 (66.1)	167 (42.4)	<0.001	0.89	0.96	0.55- 1.69
Surgery in Past 3 Months	31 (27.8)	25 (6.3)	<0.001	0.27	1.64	0.67- 4.07

Either Tolerance Gene	49 (43.8)	117 (29.6)	0.006	0.39	1.24	0.75- 2.09
<i>smr</i>-Positive	29 (25.9)	71 (18)	0.08			
<i>qacA/B</i>-Positive	25 (22.3)	54 (13.7)	0.03			
Any CHG Exposure in Past 3 Months	34 (30.3)	15 (3.8)	<0.001	0.83	1.1	0.37- 3.24
Methicillin-resistance	48 (42.8)	216 (54.8)	0.03	0.32	0.77	0.47- 1.28
Vancomycin MIC \geq 2μg/ml	4 (3.5)	8 (2)	0.3			

15

16